Home
This site is intended for healthcare professionals

Key Clinical Summary: Diagnosing PMG with Confidence

This is a summary of Enduring Module presented by expert Dr. Abigail N. Schwaede which you can find here: Module 1: Diagnosing PMG with Confidence

Before participating, please read our CME and disclosure information which can be found in the link above.

This program is supported by an independent education grant from ArgenX. This online education program has been designed for healthcare professionals in the US.

Pediatric myasthenia gravis (PMG) is an autoimmune disorder of neuromuscular transmission characterized by fluctuating, fatigable muscle weakness that worsens with exertion and improves with rest. Presentation and antibody profiles vary markedly by age of onset: prepubertal children (under approximately 12 years of age) frequently present with isolated ocular symptoms and higher rates of initial seronegativity, whereas peri- and postpubertal adolescents more often present with generalized weakness, anti-acetylcholine receptor (AChR) seropositivity, and a marked female predominance.

Differentiating PMG from Congenital Syndromes and Neuromuscular Mimics

Accurate differentiation of PMG from genetic, neonatal, and structural mimics prevents inappropriate interventions and guides treatment.

Clinical Feature Autoimmune PMG Congenital Myasthenic Syndromes (CMS) Transient Neonatal Myasthenia
Typical Onset Acute or subacute; any age under 18 years Usually before 3 years of age; lifelong course First days of life; born to a mother with MG
Ocular Exam Asymmetric, variable ptosis; diplopia Symmetrical ptosis; static ophthalmoplegia; minimal diplopia Variable ptosis accompanied by weak suck, cry, and hypotonia
Clinical Course Fluctuating with acute exacerbations; spontaneous remission possible in young children Static or slowly progressive; often stabilizes after early childhood Transient and self-limiting over weeks to months
Antibody Profile Frequently positive (AChR, MuSK, clustered AChR); 10% to 40% initially seronegative on standard assays Negative Transplacentally acquired maternal AChR antibodies
Response to Immunotherapy Responsive (corticosteroids, steroid-sparing agents) Ineffective Not indicated (except in rare cases eg plasma exchange)
Response to Pyridostigmine Beneficial in most AChR-positive cases; poor response or exacerbation in MuSK-positive PMG Subtype-dependent: beneficial in some, but worsens slow-channel, COLQ, and DOK7 syndromes Typically not required
  • Non-Discriminatory Tests: An electrophysiologic decrement on repetitive nerve stimulation (RNS) and clinical improvement following pyridostigmine both demonstrate a neuromuscular junction transmission defect, but neither test differentiates autoimmune PMG from CMS.
  • Red Flags Warranting Re-evaluation for Mimics: Findings that argue against autoimmune PMG include onset present directly at birth, parental consanguinity or affected siblings/parents, fixed or symmetrical deficits, contractures, scoliosis, orbital pain, proptosis, or absence of response to escalating immunotherapies.
  • Differential Diagnostic Considerations:
    • Ocular-Predominant Weakness: Congenital ptosis, cranial nerve III palsy, and mitochondrial disorders such as chronic progressive external ophthalmoplegia (CPEO).
    • Generalized Weakness: Congenital myopathies, mitochondrial cytopathies, Guillain-Barré syndrome (GBS), and functional neurological disorders. In contrast to typical GBS (ascending, symmetric lower-extremity weakness with hyporeflexia and sensory changes), MuSK-antibody-positive PMG presents with a "top-down" distribution of prominent facial, bulbar, and neck flexion weakness with preserved deep tendon reflexes and normal sensory examination.

Diagnostic Evaluation in Typical, Atypical, and Seronegative Presentations

Bedside Clinical Examination

  • Targeted Ocular Fatigability Signs: Examine for lid drop during sustained upgaze (60 seconds), Cogan's lid twitch (overshoot of the upper lid following rapid saccade from downgaze to primary position), and the curtain sign (worsening ptosis in the contralateral eye when the more ptotic eyelid is manually elevated).
  • Ice Pack Test: Application of an ice pack over the ptotic eyelid for up to 5 minutes yields transient improvement in lid elevation, supporting localized neuromuscular junction dysfunction.
  • Systemic Screening: Screen systematically for speech changes (nasal speech worsening upon counting aloud), dysphagia (prolonged meals, choking on liquids such as with the Slurp test), dropped-head syndrome from neck weakness, reduced single breath count, or proximal muscle fatigue (difficulty climbing stairs or raising arms overhead or sustaining shoulder or hip flexion or difficulty performing repetitive squats).

Stepwise Serologic Ladder

Because standard radioimmunoassays (RIA) miss up to 40% of pediatric cases, serologic testing should follow a tiered ladder:

  1. Step 1: Serum AChR binding antibodies via standard RIA.
  2. Step 2: Serum muscle-specific kinase (MuSK) antibodies if AChR antibodies are undetectable. Steps 1 and 2 are often done together if high suspicion at first assessment.
  3. Step 3: Cell-based assays (CBA) for clustered AChR and MuSK antibodies via a reference laboratory if standard assays are negative.
  4. Step 4: Serial serologic retesting every 6 months, as seroconversion can occur up to 5 years following symptom onset.

Pediatric-Adapted Neurophysiology

  • Low-Frequency Repetitive Nerve Stimulation (3 Hz): A decremental response greater than 10% (laboratory-dependent) in compound muscle action potential (CMAP) amplitude supports a neuromuscular transmission defect. Sensitivity is maximized by testing a clinically weak muscle and holding pyridostigmine prior to testing when safe. (Low motor amplitudes at baseline in young muscles lead to a higher chance of a false-positive due to technical artifact.)
  • Single-Fiber Electromyography (SFEMG): A specialised test with high sensitivity for increased jitter and impulse blocking. While voluntary SFEMG requires cooperative older children, stimulated SFEMG does not require patient cooperation and demonstrates up to 92% diagnostic sensitivity in PMG. Normal jitter in a clinically weak muscle strongly rules out myasthenia; however, abnormal jitter is not etiologically specific and occurs in active reinnervation, myopathies, or prior botulinum toxin exposure. Jitter norms in young children are not clearly established.

Two-Line Framework for Seronegative PMG

Diagnosis of seronegative PMG relies on converging evidence of impaired neuromuscular transmission and an immune-mediated mechanism:

  • Line 1 (Neuromuscular Junction Transmission Defect): Supported by a significant decremental response on 3 Hz RNS or elevated jitter on SFEMG, together with clinical findings such as fatigability on examination or objective improvement following a cholinesterase inhibitor trial. These findings demonstrate neuromuscular junction dysfunction but do not establish an autoimmune cause.
  • Line 2 (Immune-Mediated Mechanism): Supported by subsequent antibody seroconversion, concurrent autoimmune disease, or a clear therapeutic response to immunotherapy (e.g., corticosteroids). Response to immunotherapy alone does not confirm an autoimmune diagnosis.

All pediatric patients with confirmed or suspected PMG should undergo chest CT or MRI to screen for thymic pathology. If generalized weakness onset occurs before 3 years of age, consanguinity is present, generalized weakness occurs without severe bulbar involvement, or immunosuppression fails, prioritize next-generation sequencing genetic panels for CMS.

Referral and Diagnostic Pathways to Minimize Delays

Standardizing clinical pathways accelerates specialized diagnostic workups and mitigates

Clinical Referral & Diagnostic Pathway: Suspected Pediatric Myasthenia Gravis (PMG)

1. Initial Triage & Risk Assessment

Examine for acute red-flag symptoms: bulbar palsy, dyspnea/breathlessness, choking, or rapidly progressive weakness.

  • If High-Risk Features Are Present (YES):
    • Same-Day Emergency Transfer: Urgent emergency department evaluation and immediate cardiorespiratory stabilization.
    • Urgent Inpatient Neurology: Immediate specialist consultation for impending myasthenic crisis.
  • If Stable / Isolated Ocular or Mild Generalized Symptoms (NO):
    • Prompt Pediatric Neurology Referral: Initiate prompt outpatient subspecialty referral.
    • Critical Rule: Do not wait for antibody results to return before placing the referral.

2. Primary & Urgent Care Actions (At Time of Referral)

  • Initial Serology: Order serum acetylcholine receptor (AChR) binding antibodies.
  • Document Fluctuation: Instruct caregivers to take photographs or videos showing diurnal changes (e.g., morning vs. evening ptosis or fatigue with activity).
  • Medication Audit: Review the child's complete medication list and identify/avoid drugs that worsen neuromuscular junction transmission.

3. Specialist Comprehensive Evaluation (Pediatric Neuromuscular)

  • Stepwise Serologic Ladder:
    • AChR binding antibodies (radioimmunoassay)
    • MuSK antibodies if AChR-negative
    • Cell-based assays (CBA) for clustered AChR and MuSK antibodies
    • Serial antibody re-testing every 6 months for seronegative cases
  • Pediatric-Adapted Neurophysiology: Low-frequency (3 Hz) repetitive nerve stimulation (RNS) +/- stimulated single-fiber EMG (SFEMG) to document a neuromuscular transmission defect.
  • Thymic Imaging: Mediastinal CT or MRI for all pediatric patients to screen for thymic pathology.
  • Severity Scoring: Establish a baseline quantitative clinical score to guide immunotherapy.

4. Multidisciplinary Care Coordination

  • Pediatric Ophthalmology: Early evaluation to screen for and prevent stimulus-deprivation amblyopia in young children with ptosis and ophthalmoparesis.
  • Patient & Family Education: Structured education on illness triggers, emergency warning signs, and contraindicated medications.

Emergency Triage: Rapidly progressive weakness, nasal regurgitation, dysarthria, choking on secretions, or dyspnea require immediate emergency department presentation and same-day neuromuscular evaluation due to high impending risk of myasthenic crisis.

  • Primary Care Workup: Routine evaluation should never be delayed while waiting for antibody results to return. Primary clinicians should obtain parent photographs or video documentation demonstrating diurnal eyelid or facial fluctuation, initiate initial AChR serology, document a full medication history to avoid neuromuscular-blocking drugs, and refer promptly to pediatric neurology.
  • Multidisciplinary Specialist Collaboration: Comprehensive management pairs pediatric neuromuscular care with early pediatric ophthalmology consultation to prevent irreversible amblyopia in young children with persistent ptosis and ophthalmoparesis, alongside formal caregiver education detailing trigger avoidance and medications known to exacerbate neuromuscular transmission failure.

Content is accurate as of the date of release